$4.3 billion Biogen Idec has announced the appointment of two new members to its board: Eric Rowinsky and Stephen Sherwin. Icahn Partners, led by activist investor Carl Icahn, proposed Rowinsky as a nominee, while Sherwin was selected by the company.
Rowinsky has served as a director at Adventrx Pharmaceuticals since February 2008, recently serving as executive vice president of clinical development and regulatory at ImClone Systems Incorporated, a wholly-owned subsidiary of Eli Lilly and Company. Prior to joining ImClone Systems in 2005, Rowinsky focused his academic efforts in cancer drug development as the director of clinical research and later director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair for Early Drug Development from 1996 to 2005.
